Drugs / Polyene Phosphatidylcholine
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05476094 | Aug 2022 → Aug 2023 | — | AMIpharm Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05266729 | Mar → Dec 2022 | — | AMIpharm Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06256445 | Mar → Jul 2024 | — | AMIpharm Co., Ltd. | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT07150624 | Nov 2025 → Dec 2026 expected | hepatocellular carcinoma | Anhui Provincial Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT04595916 | Apr → Oct 2020 | drug-induced liver injury | Sichuan Haisco Pharmaceutical Group Co., Ltd | Completed | No outcome recorded |
| Phase 4 | NCT01436539 | Sep 2011 → Mar 2013 | chronic hepatitis B virus infection | Jun Cheng | Unknown | No outcome recorded |
| Comparator or background therapy8 trials | ||||||
| Phase 1/2 | NCT01844063 Background | Jul 2013 → Jan 2016 | liver failure | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2 | NCT07303803 Background | Jan 2026 → Dec 2030 expected | metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus | Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT02944552 Comparator | Aug 2017 → Jun 2019 | drug-induced liver injury | Drug Induced Liver Disease Study Group | Completed | Met primary |
| Phase 3 | NCT05063500 Comparator | Dec 2021 → May 2023 | drug-induced liver injury | Drug Induced Liver Disease Study Group | Unknown | No outcome recorded |
| Phase 4 | NCT04553003 Comparator | Aug 2020 → Apr 2025 | drug-induced liver injury | Li Yang | Unknown | No outcome recorded |
| Phase 4 | NCT02024295 Comparator | Dec 2013 → Dec 2015 | alcoholic hepatitis | Zhejiang Hisun Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT02331745 Background | Oct 2013 → Apr 2016 | alcoholic liver disease, hepatitis B virus infection, liver failure | Beijing 302 Hospital | Unknown | No outcome recorded |
| — | NCT06922669 Background | Jun 2025 → Mar 2027 expected | drug-induced liver injury | General Hospital of Shenyang Military Region | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-07-14 | Haisco Pharmaceutical Group Co., Ltd. | Regulatory 多烯磷脂酰胆碱注射液进入新版国家基药目录 haisco.com ↗
多烯磷脂酰胆碱注射液（商品名：思复®）成功进入目录，成为5款进入目录的肝病治疗药之一。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-07-14 | Haisco Pharmaceutical Group Co., Ltd. | 多烯磷脂酰胆碱注射液进入新版国家基药目录 haisco.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Polyene Phosphatidylcholine | “Standard treatment includes reduced glutathione, glycyrrhizin, ademetionine,polyene phosphatidylcholine, alprostadil, and human serum albumin) on the day of admission.” NCT02331745 ↗13“B.Hepatoprotective drugs(Ademetionine1,4-butanethiosulfonate for Injection, Reduced Glutathione for Injection,Polyene Phosphatidylcholine, et al)” NCT01844063 ↗ “Receiving 930mg of polyene phosphatidylcholine injection one day before the operation,twice a day.” NCT07150624 ↗ “Polyene Phosphatidyl choline” NCT04553003 ↗ |
| Known as | PPC | “Adefovir Dipivoxil 10 mg once daily for 48 weeks plus Polyene phosphatidylcholine (PPC) 456 mg three times per day for 48 weeks” NCT01436539 ↗ |
| Modality | Small molecule | — CHEMBL2107953 ↗ |
| Route | Intravenous | “Polyene Phosphatidyl choline 10ml ivgtt qd for 2 weeks” NCT02024295 ↗ |